Bluebird bio Overview
Bluebird bio (BLUE) has a ROE of 345.59%, above the Healthcare sector average of 20.86%.
Get informed when a big investor buys or sells
+ Follow345.59%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Bluebird bio (BLUE) currently reports a ROE of 345.59%. That is above the Healthcare sector average of 20.86%. Use the charts on this page to explore Bluebird bio's ROE history and peer comparisons.
Bluebird bio's ROE of 345.59% is higher than the Healthcare sector average of 20.86%. That is roughly 1557.0% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Bluebird bio's current 345.59% should be judged against Healthcare norms (sector average: 20.86%) and against BLUE's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 345.59%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 20.86%. From there, open related valuation or income-statement pages for Bluebird bio, and consider following BLUE for alerts when major investors trade the stock.
Bluebird bio is classified in the Healthcare sector. On ROE, it currently shows 345.59% versus a sector average near 20.86%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BLUE with unrelated industries.
